bpc 157 human evidence safety fda warning may take an important step toward opening the peptide floodgates this week bpc-157 human clinical trials safety

Suarez et al., 2016)

The combination of unverified formulation, uncertain sterility, and unknown systemic effects creates a perioperative exposure that cannot be reliably risk-stratified

Eur J Gen Pract (2006) 12(4):16973.10.1080/14017430601049449 24 Sanz-CuestaTGonzalez-EscobarPRiesgo-FuertesRGarrido-ElustondoSdel Cura-GonzalezIMartin-FernandezJet alOral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial undertaken in the primary healthcare setting (project OB12)

38 This pain commonly presents as spontaneous burning sensations in the feet, and patients may also report positive sensory symptoms such as brush-evoked allodynia (pain from normally non-painful stimuli) and paresthesias, which are often accompanied by sensory loss, leading patients to describe the paradox of their feet being continuously painful yet insensate to touch

Anyone using BPC-157 is self-experimenting based on strong animal data and anecdotal human reports